| Literature DB >> 31711981 |
Victor Martin1, Isabel A C Ribeiro1, Marta M Alves2, Lídia Gonçalves1, António J Almeida1, Liliana Grenho3, Maria H Fernandes3, Catarina F Santos4, Pedro S Gomes3, Ana F Bettencourt5.
Abstract
Periodontal diseases remain a challenge due to a complex interplay of factors involving a chronic inflammatory activation and bacteria internalization in periodontal cells. In this work, chitosan-nanoparticles loaded with minocycline (MH-NPs), a tetracycline with antimicrobial and anti-inflammatory effects, were developed for in situ delivery in the periodontal milieu aiming to improve drug effectiveness. A general cytocompatibility evaluation and a detailed approach to address the cellular uptake process, trafficking pathways and the modulation of relevant inflammatory gene expression was conducted using human gingival fibroblasts. Results show that MH-NPs with an adequate cytocompatible profile can be internalized by distinct endocytic processes (macropinocytosis and clathrin-mediated endocytosis). The ability to modulate autophagy with the delivery within the same endosomal/lysosomal pathway as periodontal pathogens was observed, which increases the intracellular drug effectiveness. Porphyromonas gingivalis LPS-stimulated cultures, grown in the presence of MH-NPs, were found to express significantly reduced levels of inflammation-related markers (IL-1b, TNFα, CXCL-8, NFKB1). These nanoparticles can be potentially used in periodontal disease treatment conjoining the ability of intracellular drug targeting with significant anti-inflammatory effects.Entities:
Keywords: Chitosan; Inflammation; Intracellular-target delivery; Minocycline; Perioceutics; Periodontitis
Mesh:
Substances:
Year: 2019 PMID: 31711981 DOI: 10.1016/j.ijpharm.2019.118821
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875